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INTRODUCTION
HIV-1 protease (HIVp) remains an important pharmaceutical target.
Despite the existence of 10 protease inhibitors (PIs) in clinical use,1
there is little difference in their mechanism of action. Typical PIs are
pseudosymmetric and compete with the substrate for binding at the
base of the active site. Unfortunately, even the most recent PIs suffer
from taxing side effects, poor pharmacokinetic properties, and develop-
ment of drug resistance.2,3 There remains a need to discover novel ther-
apeutics, especially compounds that bind in nontraditional modes and
have the potential to target both wild-type and multidrug-resistant
(MDR) mutants and overcome resistance mechanisms.
The protease is a C2 symmetric dimer with the characteristic catalytic
acids at the base of its active site. The active site is covered by two anti-
parallel b-hairpin turns, called the flaps (residues 43–58/430–580). The
conformation of these flaps has been well-studied, and researchers have
linked flap motion to activity of the protease.4 The flaps exist in three
major conformations: open, semiopen, and closed. Structural studies
have shown the semiopen conformation to be most populated in the
native, apo state.5–8 The flaps shift 5–7 Å in position on ligand binding
and assist in its proper placement within the active site. Studies have
shown that there is little difference in free energy between the three flap
conformations.9 Researchers have shown that differences in flap mobility
are a potential contribution to the mechanism of MDR for certain HIVp
mutants.10 Thus, the possibility exists that protease activity can be easily
affected by controlling flap conformation. By targeting HIVp through al-
losteric inhibition, it may be possible to avoid some of the difficulties
that plague traditional PIs. Therefore, it is essential to investigate how
compounds can alter flap behavior.
Böttcher et al.11 recently reported an interesting crystal structure
demonstrating the simultaneous binding of two symmetric pyrrolidine
diester inhibitors to the open-flap conformation of HIVp (PDB ID
3BC4). One is bound bridging the traditional active site and the ‘‘eye’’
site,12 while the other is bound between the flaps [Fig. 1(A)]. The
bridged binding pose places two naphthyl rings into each eye site [Fig.
1(B)], lending support to the possibility of targeting this for inhibitor
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ABSTRACT
A recent crystal structure of HIV-1 protease
(HIVp) was the first to experimentally
observe a ligand targeting an open-flap con-
formation. Researchers studying a symmetric
pyrrolidine inhibitor found that two ligands
cocrystallized with the protease, forcing an
unusual configuration and unique crystallo-
graphic contacts. One molecule is centered
in the traditional binding site (a pose) and
the other binds between the flaps (b pose).
The ligands stack against each other in a
region termed the ‘‘eye’’ site. Ligands bound
to the eye site should prevent flap closure,
but it is unclear if the pyrrolidine inhibitors
or the crystal packing are causing the open
state. Molecular dynamics simulations were
used to examine the solution-state behavior
of three possible binding modes: the ternary
complex of HIVp1ab and the binary com-
plexes, HIVp1a and HIVp1b. We show that
HIVp1a is the most stable of the three
states. During conformational sampling, a
takes an asymmetric binding pose, with one
naphthyl ring occupying the eye site and the
other reoriented down to occupy positions
seen with traditional inhibitors. This finding
supports previous studies that reveal a
requirement for asymmetric binding at the
eye site. In fact, if the a pose is modified to
splay both naphthyl rings across the binding
site like traditional inhibitors, one ring con-
sistently flips to occupy the eye site. Our
simulations reveal that interactions to the
eye site encourage a conformationally
restrained state, and understanding those
contacts may aid the design of ligands to
specifically target alternate conformations of
the protease.
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design. Although the authors did not propose that this
was necessarily a 2:1 complex in solution phase, the crys-
tal structure merits investigation.
We originally proposed the eye site as a possible new
mode of HIVp inhibition.12 Our interest in designing
compounds to target the eye site motivated us to study
the conformational states occupied by this receptor–
ligand complex in solution. Our goal is to explore the
effect of these inhibitors on the conformation of the
flaps. It is important to determine whether the confor-
mation seen in the crystal structure is also seen in simu-
lation when symmetry-related contacts of the crystal
structure are absent. Retaining the notation used by
Böttcher et al., we examined the two inhibitors bound to
HIVp from the crystal structure (ab), as well as a single
inhibitor bound bridging the active site (a) or in the
alternate position against the flaps (b). We hypothesize
that the b pose is neither stable, nor is the ternary crystal
complex, given the poor contacts available to b without
the influence of crystal contacts.
METHODS
Our molecular dynamics (MD) protocol was based on
work by Meagher et al.13 Our simulations were based on
the protein structure crystallized by Böttcher et al. (PDB
ID 3BC4). PyMOL14 was used to propagate the asym-
metric unit cell. A combination of PyMOL and MolPro-
bity15 was used to check/flip protonation states while
MOE16 was used to modify the number of bound
ligands. The catalytic aspartic acids were both deproto-
nated, as is appropriate in the presence of the positively
charged ligand.
For each inhibitor-binding state (ab, a-only, or
b-only), eight independent, explicit-solvent simulations
were performed. Parameters for the inhibitor were gener-
ated in antechamber with the Gaff force field17 and
AM1-BCC charges.18 Hydrogens were built in the tleap
module of AMBER.19 TIP3P waters20 were added as an
orthogonal box with a 12 Å buffer to solvate the system.
APBS-1.0.021 via the plugin for PyMOL22 was used to
calculate an electrostatic surface 10 Å from the vdw sur-
face of the protein, and chloride ions were placed at the
most electropositive regions to neutralize the 14e charge
of the protein and the 11e charge of each ligand. MD
simulations were performed in the sander module of
AMBER using the ff99sb force field23 and a timestep of
2 fs. A nonbonded cutoff was applied at 10 Å. Particle
Mesh Ewald24 was implemented, and bonds to hydrogen
were constrained with SHAKE. Water was equilibrated
prior to complete system equilibration to prevent protein
collapse.13
Following minimization of hydrogens, then side chains
and then the full system, equilibration was performed
with a gradual removal of backbone restraints to achieve
Figure 1
(A) The crystallized HIV-1 protease uniquely bound by two identical
inhibitors, with pose a colored in gray and pose b in black. (B) The
crystal structure 3BC4 with Damm compound 112 (black) bound at the
eye site. (C) The 5-nitroindole fragment (black) crystallized in the eye
site by Perryman et al.28 (D) A two-dimensional representation of the
pyrrolidine inhibitor that was cocrystallized with 3BC4. The affinity
(Ki) of the compound for HIVp was measured by Klebe and coworkers
as 20 lM (WT), 41 lM (I50V), and 4.5 lM (I84V).11 For the
following figures, we have used a convention of orienting the complex
so that a naphthyl occupies the eye position on the right (i.e.,
monomer 2). We are labeling the monomers as ‘‘1’’ and ‘‘2’’ instead of
‘‘A’’ and ‘‘B’’ to avoid confusion with the a and b notation for the
ligands.
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a stable trajectory. Over 500 ps, the protein–ligand–sol-
vent system was gradually heated from 10 to 310 K, and
backbone restraints were gradually softened from 2.0 to
0.1 kcal/mol Å in a total of five steps. After a two nano-
second (ns) equilibration of the protein with no
restraints, the production phase lasted for 25 ns. This
resulted in a total of eight individual simulations of 25
ns for each of the three sets of bound systems. Therefore,
200 ns of total production time was collected for the
HIVp1a complex, HIVp1b complex, and ternary
HIVp1ab complex.
Trajectories were analyzed using the AMBERTOOLS
package. Ptraj allows for clustering simulations to deter-
mine the most prevalent conformations sampled within a
specified time period.25 The trajectories were centered and
aligned to the core of the protease (residues 1–45, 55–99,
10–450, and 550–990). The last 5 ns from each simulation
for each complex were then clustered together with refer-
ence to the initial structure. Several clustering protocols
were performed to determine the optimal algorithm and
family size based on measures of the Davies–Bouldin
index,26 pseudo F-statistic,27 and percentage of variance.
Clustering the simulations into 10 families based on the
average-linkage algorithm was judged to give the best per-
formance. Ptraj was also used to evaluate the degree of
flap opening, flap curling, ligand placement, and protein
stability (see Supporting information).
RESULTS AND DISCUSSION
The recent crystal structure from Klebe and coworkers
provided the first experimental support of the eye site as
a target.11 The naphthyl rings of the two inhibitors crys-
tallized into each eye site, confining the flaps to the semi-
open conformation. Due to the implications of crystal
packing effects, we performed MD simulations to deter-
mine the conformational behavior of both 1:1 and 2:1
complexes in solution. We were most interested in the
stability of the different potential complexes, the impact
of the inhibitor(s) on flap conformation, and the poten-
tial for selective binding at the eye site region.
The impact of bound inhibitors at positions a, b, and
ab was examined over a series of eight unique simulations
for each ligand pose. Simulations of a-only and b-only
were examined as representatives of possible 1:1 complexes
as compared to the 2:1 HIVp1ab complex. The impact
of inhibitor binding on backbone stability over the course
of each simulation was measured by determining the Ca
root mean square deviation (RMSD) of the core residues
from the initial crystal structure (see Supporting Informa-
tion Fig. S1). For the three different systems, the RMSD
of the protease core is 1.65  0.28 Å (HIVp1ab), 2.25 
0.35 Å (HIVp1b), and 1.81  0.25 Å (HIVp1a), signify-
ing core stability. The flaps were mobile as expected (see
Supporting Information Figs. S2–S4).
The impact of the ligands on the conformational en-
semble was examined through clustering of the confor-
mations sampled over the simulation trajectory. The
atomic fluctuations of the protein for the complete simu-
lation were calculated with ptraj to define the stable core
residues. The trajectory was imaged and Rms-fit to the
protease backbone, and then ptraj was used to cluster the
heavy atoms of the stable protease core and the ligand
over the last 5 ns of each 25 ns trajectory. Clustering the
final 10 ns of the trajectory together required too much
system memory; however, conformations observed from
the last 10 ns of individual runs were in agreement with
clustering over all runs. A total of 10 families were gener-
ated using the average-linkage algorithm. This was
accomplished for all simulations of the HIVp1ab, the
HIVp1a, and the HIVp1b complexes. The representa-
tive structures were then examined to determine the sim-
ilarity between binding modes among the families. In
addition, calculations were performed to assess the stabil-
ity of the bound ligands over time (see Supporting Infor-
mation Figs. S5 and S6). The RMSD of each ligand was
calculated against the average ligand position as well as
the crystallographic pose. All values were calculated for
the final 5 ns of each trajectory.
HIVp1ab
The 2:1 complex of HIVp1ab is unstable. The repre-
sentative conformations illustrate a wide range of motion
sampled by the b ligand and a moderate amount of sam-
pling by the a ligand. Compared to the average ligand
position, the RMSD of the a ligand over the last 5 ns
ranged from 1.04 to 15.41 Å and b ligand ranged from
1.07 to 28.28 Å. The large fluctuation in position of the
ligands illustrates the instability of the HIVp1ab com-
plex and hints at the instability of the binary HIVp1b
complex as well. Analysis of the conformations present in
representative families show that in our HIVp1ab simu-
lations, the a ligand has one naphthyl that occupies the
eye site and the other naphthyl in the S1 or S2 pocket in
approximately 62% of the sampled trajectory (Fig. 2).
The b ligand in these simulations is quite varied in posi-
tion; contacts are typically maintained between the pyr-
rolidine amino group and flap tips or solution.
As our interest lay in understanding the impact of
these inhibitors on flap conformation, we quantified flap
motion over time. A common standard for evaluating
flap conformation is the distance between the flap tips
(Ile50/500) and the catalytic aspartic acids (Asp25/250).10
A typical distance for the closed flap form, based on the
crystal structure 1PRO, is 14.1 Å. A typical distance for
the semiopen form, based on the crystal structure 1HHP,
is 17.8 Å. Over the last 5 ns, the HIVp1ab simulations
sampled a median distance of 20.81 and 17.18 Å for
monomers 1 and 2, respectively, implying an asymmetric,
semiopen flap conformation for the duration of produc-
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Figure 2
Representative structures from the MD simulation of the HIVp1ab complex, taken from the last 5 ns of each 25 ns trajectory. The a ligand is
shown in green, the b ligand is shown in black, the S1/S10 site is shown in yellow, and the S2/S20 site is shown in purple. The conformational
families demonstrate the instability of the 2:1 bound complex. The pyrrolidine ligands find a wide variety of ways to interact with the protease
flaps, S1/S10, S2/S20, and/or the eye site.
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tion time. The flap RMSD for the 2:1 complex demon-
strates a considerable range of motion, with a mean of
3.71  0.98 Å relative to the crystal structure.
As expected, the ternary complex of HIVp1ab was
not stable. Klebe and coauthors, in their experimental
work, did calculate their affinity data using a 1:1 ratio
for kinetics. In a 1:1 ratio, the bound state is expected to
be more similar to other holo crystal structures than the
solved 3BC4 crystal structure. Klebe and coauthors also
concluded their study with a discussion of the possible
influence of crystal packing on the crystallographic con-
formation and its potential instability in solution. In the
crystal structure itself, it appears that the majority of
symmetry-packing contacts are formed through ligand–
ligand stacking. It may be that these contacts stabilize the
observed bound handedness while requiring a semiopen
flap elevation.
HIVp1b
Simulations of the b-only complex reveal a wide varia-
tion in the population ensemble. None of the representa-
tive structures occupy the same conformation as the crys-
tallographic ligand position (see Supporting Information
Fig. S7). Over the last 5 ns, the deviation of the ligand
from the average pose is in the range of 1.73–7.56 Å,
which shows that the b ligand alone is unstable, and this
instability is reflected in the diversity of populated states
from these simulations. While the b ligand samples
widely, it always has a naphthyl ring in the eye site. The
other moieties on the ligand are primarily involved in
forming hydrophobic interactions with residues in the
flap region. The presence of the b ligand skews the flaps
asymmetrically, which is consistent with our previous
simulation and proposed behavior of the eye site.11
Our simulations show that when bound alone, the
pyrrolidine ligand is not likely to bind in the crystallo-
graphic b pose. The system is not stably bound, and the
ligand moves to more favorable conformations. This can
be seen from both the representative structures of the
HIVp1b complex as well as the high RMSD of the
ligand from the average conformation.
During the b simulations, the flaps display semiopen
to open behavior with averages over the last 5 ns for flap
tip to catalytic aspartic acid distance of 20.39 and 15.43
Å for monomers 1 and 2. The conformation of the more
open flap is explained by the presence of the b ligand
and its flap recognition pocket, which prevents tradi-
tional flap dynamics. The ligand interactions at the eye
site skew the flaps of the protease into an asymmetric
conformation. Over the last 5 ns, the average RMSD of
the flap residues to the crystal position for the b-only
simulation is 4.73  1.06 Å, illustrating similar motion
to that sampled by the HIVp1ab complex.
The b-only complex is far less favorable than the a-
only complex. In fact, in one of the b-only simulations,
the ligand flips to occupy the a pose (Supporting Infor-
mation Fig. S7b), and in the other seven simulations of
b-only, several representative states have the ligand in
poses that are similar to the a state (e.g., Supporting In-
formation Fig. S7e).
HIVp1a
In the a-only simulations, the distance between the
flap tips and catalytic asparatic acids is usually between
15–16 Å. This signifies that over the course of our simu-
lations the flaps sample conformations in between closed
and semiopen. They cannot close completely due to the
presence of the ligand in an eye site. The flaps themselves
have an average RMSD of 4.44  0.47 Å to the crystal
structure, over the last 5 ns. The low standard deviation
signifies the greater stability of flap conformation
throughout these simulations of the a-only complex, rel-
ative to the ab and b-only simulations.
It is interesting that the most frequently sampled con-
formations in the a-only case illustrate a preference for
asymmetric binding at the eye region (Fig. 3). We find
that one of the naphthyl rings of the ligand often reor-
ients in a manner similar to positions of aromatic rings
in known PIs. One naphthyl ring of the Klebe inhibitor
remains stably bound at the eye site, while the second
naphthyl ring dissociates from an eye site to occupy
either the S1 or S2 site in approximately 75% of the sim-
ulation time sampled [Fig. 3(A,B)]. In addition to dem-
onstrating a possible need to satisfy interactions at either
the S1 or S2 binding pocket, this also agrees with two
recent studies that illustrate a requirement for asymmet-
ric binding to the eye site.12,28
There is moderate deviation from the average ligand
position in simulations of HIVp1a over the last 5 ns,
with a range of 1.78–5.86 Å. The loss of one naphthyl
ring from an eye site results in the difference from the
crystallographic pose. A low standard deviation of 0.73 Å
validates the greater stability of this binding pose. RMSD
values for the two naphthyl rings were calculated to bet-
ter demonstrate alterations in ligand binding over time
for the a-only case. RMSD traces were created to detail
the naphthyl ring position of ligand over time. The a
ligand was fairly stable over time (see Supporting Infor-
mation Fig. S4), and the RMSD of the naphthyl rings
clearly shows the continued binding of one ring in the
eye site [Fig. 4(A)] and the absence of binding at the
other eye site [Fig. 4(B)]. In the least populated confor-
mational family, both sides of the ligand do flip down
into the traditional binding pocket [Fig. 3(E)]. This indi-
cates that sufficient sampling has occurred and that this
pose is less preferred than asymmetric binding to the eye
and S1 or S2 site.
Of course, it is possible that we observed incomplete
sampling, and the inhibitor could actually prefer to be
‘‘extended’’ with both naphthyl rings occupying S1 and/
K.W. Lexa and H.A. Carlson
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or S2 sites. To determine this, we conducted a fourth
series of MD. This system, HIVp1a0, was obtained by
modifying the HIVp1a crystal pose to flip both naph-
thyls into the S2/S20 pockets. HIVp1a0 was subjected to
hydrogen minimization in the gas phase with AMBER to
ensure that the MD simulations commenced from an
unstrained system [Fig. 5(A)]. After this, the setup and
simulation of the HIVp1a0 complex followed the previ-
ously described protocol for complexes HIVp1a,
HIVp1b, and HIVp1ab. Again, eight independent sim-
ulations were conducted, and the last 5 ns of each simu-
lation were examined.
These additional simulations, beginning with both
naphthyl rings interacting at the S2/S20 pockets, resulted
in at least one ring altering its position during simulation
to interact with the eye region [Fig. 5(B–F)]. The most
populated family type is extremely similar to the most
populated families from HIVp1a complex simulations:
wherein one ring interacts at the eye region while the
other interacts at the S2 pocket. It is possible that the
naphthyl rings are positioned one up and one down in
solution. NMR data might show whether or not there is
symmetry of the two rings’ environment in solution. We
found that in the ternary complex, even in the presence
of the b ligand, one side of a flips down to occupy a
similar position to known inhibitors.
It is interesting to note that all of the protease confor-
mations in the clustered families display flaps with the
Figure 3
Representative structures from the MD simulation of the HIVp1a complex, taken from the last 5 ns of each 25 ns trajectory. The a ligand is
shown in green, the S1/S10 site is shown in yellow, and the S2/S20 site is shown in purple. The conformational families for the a ligand illustrate its
strong preference for forming one interaction between the naphthyl ring and the eye site, while the other naphthyl ring flips to interact at the S1/
S10 or S2/S20 site, and the pyrrole maintains a hydrogen bonding interaction with the catalytic aspartic acids.
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same handedness as the closed state. This signifies that
the protease is occupying similar conformational space of
the bound form, even though the flaps are typically in
the semiopen position (also seen in the close-handed,
wide-open structure 1TW7).29 However, this does not
mean the flaps cannot flip handedness during the simula-
tions, only that we do not observe it in the majority of
conformations viewed over the complete trajectory. The
flaps do display the type of curling commonly observed
during flap transitions. More simulation time may be
required for the flaps to flip handedness, simply because
of the presence of an inhibitor molecule bound in the
flap region.
Despite the relative instability of the crystal conforma-
tion during MD simulations, the placement of moieties
in the eye site intrigued us due to our previous work. We
find that ab and b probably do not exist, due to the
instability of b and poor contacts available to b. Consid-
erable flexibility in the flap region is observed in simula-
tions with the alternate ligand (ab and b) as compared
to the simulations with a-only. Although these molecules
have a unique crystallographic conformation, the struc-
ture in solution most likely resembles a conformer
similar to the HIVp1a complex. The a pose is far more
stable, and it most likely contacts one eye site as well as
the traditional active site. Our results provide strong sup-
port for further exploration of the eye site as a new
mode of inhibition for HIVp.
CONCLUSION
Although the original crystal structure of the pyrroli-
dine inhibitors is unlikely to exist in solution, we were
interested in exploring the potential shown by this
mode of binding because of its relationship to the eye
site. Naphthyl groups are not ideal because of solubil-
ity and metabolic issues, but these inhibitors show that
we can take advantage of the eye site in inhibitor
design. The binding assays performed by Klebe and
coauthors1 show the potential of these compounds for
targeting HIVp. Investigating all of the potential bound
states of this complex—HIVp1ab, HIVp1b, HIVp1a,
and HIVp1a0—allows for an accurate study of the
impact these ligands may have on flap conformation,
and therefore, protease activity.
Our study used 200 ns of simulation time per system
to examine the conformational stability of several HIVp–
ligand complexes based on a symmetric inhibitor from
Klebe and coauthors.10 Our present results support pre-
vious findings that indicate the existence of an alternate
binding site for HIVp: the eye site.11 Furthermore, our
data support a preference of asymmetric binding at the
eye site, as previously suggested.11,26 The representative
structures of the HIVp1a and HIVp1a0 complexes illus-
trate that only one eye site tends to be occupied, while
the other naphthyl ring prefers binding at the S1 or S2
site. This implies that traditional inhibitors could be
modified to take advantage of this interaction and/or tar-
geting the eye site may be improved by including some
traditional S1 or S2 contacts. Inhibitors with improved
contacts would be an important step toward demonstrat-
Figure 4
The overall RMSD from the crystal pose calculated for each naphthyl
ring of the ligand in HIVp1a over the length of the production run.
Trajectories were first fit to the Ca core of the 3BC4 crystal structure.
Each color represents a single production run and denotes the same run
for each plot. (A) Highlights the RMSD of the first naphthyl ring over
time and (B) highlights the RMSD of the second naphthyl ring over
time. As noted in Figure 1, we have used the convention of labeling
monomers 1 and 2 based on the behavoir of the ligand, where better
agreement with the initial position in the eye is oriented to the right in
the figures and labeled as monomer 2 in the graphs. An RMSD of
6.2–7.9 Å indicates occupation of the S2/S20 site, while an RMSD of
7.8–10.1 Å indicates occupation of the S1/S10 site.
K.W. Lexa and H.A. Carlson
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ing the viability of the eye site as a target for protease
inhibition.
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